Crohn's disease - Health Xplore

Friday, 6 November 2026

Hello world!

May 9, 2026

Pregabalin Included Under Schedule H1

May 22, 2026

Advanced Radiotherapy: Army Hospital Unveils Linear Accelerator

May 25, 2026

Neurosurgical Innovation: WFNS Committee Partners with Time Medical

May 25, 2026

Contact Info

E-MAIL: support@healthxploreindia.com
E-MAIL: healthxploreindia@gmail.com

Tag: Crohn’s disease

AbbVie Secures Global Rights to Nxera's IBD Drug Candidate in US$ 1.47 Billion Deal

News

Nxera Pharma, AbbVie Sign License Agreement for Novel IBD Drug

Under the agreement, AbbVie will receive exclusive worldwide rights to develop and commercialise Nxera’s EP4 agonist for inflammatory bowel disease.

imphoenix82
November 4, 2026
0 Comments
206 Views

About Us

HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.

Email: support@healthxploreindia.com

Contact: +91 9354115542

Hello world!

Pregabalin Included Under Schedule H1

Advanced Radiotherapy: Army Hospital Unveils Linear Accelerator

Neurosurgical Innovation: WFNS Committee Partners with Time Medical

Contact Info

Tag: Crohn’s disease

Nxera Pharma, AbbVie Sign License Agreement for Novel IBD Drug

India Proposes Immediate Suspension of Licences for Substandard.

What If Your Pregnancy Test Came With a.

Global Ophthalmic Equipment Market to Surpass US$ 30.

HIV Prevention: Dr Reddy’s Receives US FDA Tentative.

About Us

Quick Link

Top Categories

Top Posts

Laser Treatments for Anti-aging: Types, Benefits,

Lilly’s Retatrutide Shows Powerful Weight Loss

National Registry for Implantable Medical Devices: